Similar to This
Previous
Profile picture of deraktionaer.de
deraktionaer.de
Credibility C
 13h
Pfizer dividend stock: Business stagnates - | Forecast still raised: The US pharmaceutical company has published its quarterly figures for the third quarter of ...
deraktionaer.de/artikel/pharma-biotech/dividenden-aktie-pfizer-geschaeft-stagniert-prognose-dennoch-erhoeht-20431644.html
Pfizer dividend stock: Business stagnates - | Forecast still raised
0 similar articles
0
0
Profile picture of Beobachter
Beobachter
D+
 Oct 29
Doctors receive 234 million from the pharmaceutical industry: The pharmaceutical industry sponsors doctors, hospitals, and professional associations with ...
beobachter.ch/gesundheit/pharmaindustrie-verteilt-234-millionen-an-arzte-und-spitaler-977303
Doctors receive 234 million from the pharmaceutical industry
0 similar articles
4
9
Profile picture of marketwatch.com
marketwatch.com
B
 Oct 29
Looking for income? These dividend stocks have high yields that seem well supported.
trib.al/cCXVv6h
Looking for income? These dividend stocks have high yields that seem well ...
0 similar articles
0
1
0
0
0
0
0
0
Profile picture of deraktionaer.de
deraktionaer.de
C
 May 05
Pfizer dividend stock: Expectations exceeded - | Forecast confirmed: Pfizer exceeds market expectations for revenue and profit.
deraktionaer.de/artikel/pharma-biotech/dividenden-aktie-pfizer-erwartungen-uebertroffen-prognose-steht-20400305.html
Pfizer dividend stock: Expectations exceeded - | Forecast confirmed
1 similar article
0
0
Profile picture of Die Presse
Die Presse
B
 Feb 23
How much money do you need to live off dividends?: Corporations worldwide are expected to distribute around 1.8 trillion dollars to their shareholders this year ...
diepresse.com/20602015/kann-eine-dividende-wirklich-ein-zweites-einkommen-sein
How much money do you need to live off dividends?
0 similar articles
0
0
Profile picture of BÖRSE ONLINE
BÖRSE ONLINE
C
 Jan 12
These stocks promise huge profits - | in a $100 billion market: Novo Nordisk and Eli Lilly lead the weight-loss therapy market, while new competitors are ...
boerse-online.de/nachrichten/aktien/fette-gewinne--20393160.html
These stocks promise huge profits - | in a $100 billion market
0 similar articles
0
0
0
2
Profile picture of deraktionaer.de
deraktionaer.de
C
 Apr 30 24
Pfizer: double blow before the numbers - that is expected: Two approvals in a short time.
deraktionaer.de/artikel/pharma-biotech/pfizer-doppelschlag-vor-den-zahlen-das-wird-erwartet-20356527.html
Pfizer: double blow before the numbers - that is expected
Key FactsPfizer announces two approvals before quarterly results
Apr 30, 2024 · Reading time: ~30 sec.
Summary created with AI assistance · Source: deraktionaer.de
  • At the start of the week, the FDA approved Tivdak for recurrent or metastatic cervical cancer.

  • Tivdak contains tisotumab vedotin, an antibody-drug conjugate Pfizer acquired through its takeover of Seagen.

  • The previous week, the FDA approved Beqvez for adults with hemophilia B; the gene therapy costs $3.5 million.

  • On average, analysts expect $13.9 billion revenue, $3.97 billion EBIT, and earnings of $0.31 or adjusted $0.52 per share on May 8.
1 similar article
0
0
Next